Trade Mission: Advancing Norwegian radiopharma and precision oncology in Japan

This targeted trade mission brings together established Norwegian leaders in radiopharmaceuticals and precision oncology, alongside innovative scale-ups and companies across the value chain. By working as a country team, we can showcase Norway’s full strengths and drive greater visibility in Japan.

This is a unique opportunity to connect with Japanese pharma, investors, healthcare stakeholders and benefit from the joint Nordic platform during Osaka Expo 2025 Health Week.

Programme Highlights:

• Meet Big Pharma and Investors at the 4th Nordic Health Summit Japan
• Join a Roundtable on Norway–Japan collaboration in radiopharma and oncology
• Engage with Key Opinion Leaders at Nordic Health EXPO, Osaka Expo
• Tailored Programme: B2B meetings, health authority dialogues and site visits to leading Japanese biopharma companies

Why Japan?

Japan is the world’s third-largest healthcare market, with strong growth and major opportunities for partnerships.

• 125 million people – A large, ageing population driving demand.
• Steady growth – 4% CAGR (2018–2024).
• Global pharma leaders – Home to Takeda, Astellas, and Eisai.
• Robust healthcare system – Universal coverage; health spend is 11% of GDP.